Full-Time

Distribution Coordinator

Globus Medical

Globus Medical

1,001-5,000 employees

Develops musculoskeletal implants and enabling technologies

No salary listed

Sydney NSW, Australia

In Person

On-site role in Seven Hills, New South Wales; remote work not available.

Category
Operations & Logistics (1)
Required Skills
Inventory Management

Get referred to Globus Medical

See people who can refer or advise you

Requirements
  • Exceptional ability to work unsupervised
  • Attention to detail
  • Proactive driven attitude
Responsibilities
  • Co-ordinate the daily dispatch and return of loan sets in NSW as well as supporting other satellite offices around ANZ
  • Receive and inspect all incoming and outgoing loan sets to ensure they match as per the checklist
  • Liaise with sales rep and hospital CSSD staff regarding loan set delivery and loan set return.
  • Replenish consignment resupply to relevant consignment locations
  • Record all stock usage and set movements through IT portal
  • Maintain shelf inventory. Perform stock takes on inventory.
  • Ensure all surgeon preference cards are up to date and accurate.
  • Actively look to improve work flow and processes within the warehouse.
  • Ability to work to deadlines and make decisions to solve problems
  • Meticulous attention to details and can-do attitude
Desired Qualifications
  • None

Globus Medical makes medical devices for musculoskeletal issues, especially spine, orthopedic, and neurosurgical care. Its products fall into two groups: Musculoskeletal Solutions with implantable devices, biologics, and surgical instruments, and Enabling Technologies with imaging, navigation, and robotics that help plan, guide, and analyze surgeries. The company stands out by offering an integrated platform that combines implants with enabling technologies to improve surgical precision and outcomes. Its goal is to help patients recover from musculoskeletal problems while expanding its product lines and geographic reach.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Lower Providence Township, Pennsylvania

Founded

2003

Get referred to Globus Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $789.6 million, beating estimates and rising 5.9% year over year.
  • Non-GAAP EPS hit $1.34 on 2026-08-06, and management raised full-year EPS guidance.
  • Share repurchases totaled $136.1 million in Q2 2026, signaling cash generation and confidence.

What critics are saying

  • Life Spine won the Federal Circuit on 2026-06-04, weakening Globus patent leverage.
  • FDA warning letter dated 2024-07-15 targeted ExcelsiusGPS complaint handling, MDR reporting, and CAPA.
  • Severe FDA action against ExcelsiusGPS freezes a high-margin platform and cuts Globus growth engine.

What makes Globus Medical unique

  • Globus Medical pairs spine implants, robotics, and patient-specific lumbar systems after Scripps clearances on 2026-08-06.
  • ExcelsiusGPS ties navigation, imaging, and robotics into one surgeon workflow across procedures.
  • NuVasive plus Nevro create a broader spine-and-pain platform than pure-play competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 7th, 2026
Globus Medical raises EPS guidance to $5.05 despite Nevro and Enabling Tech headwinds

Globus Medical reported second-quarter 2026 non-GAAP earnings per share of $1.34, beating the $1.12 consensus estimate. Revenue of $789.61 million also exceeded expectations of $786.86 million. The company raised full-year EPS guidance to $4.95-$5.05 from $4.70-$4.80 but maintained revenue guidance at $3.18-$3.22 billion. Second-quarter revenue grew 6% overall and 9% excluding Nevro, driven by 7% US Spine growth and 14% International Spine growth. Adjusted gross margin improved to 69.4%, up 200 basis points year-over-year. Adjusted EBITDA margin rose to 35.4% from 28.0%. Management cited Nevro and Enabling Technologies as potential risks to second-half performance. Enabling Technologies revenue fell 25.8% to $26.1 million as the company shifted towards flexible capital-acquisition options.

Associated Press
Aug 6th, 2026
Globus Medical Q2 sales hit $789.6M, non-GAAP EPS jumps 55.8% to $1.34

Globus Medical reported second quarter 2026 worldwide net sales of $789.6 million, up 5.9% year-over-year, or 5.6% on a constant currency basis. GAAP diluted earnings per share fell 26.2% to $1.10, primarily due to a $110.5 million bargain purchase gain from the Nevro acquisition in the prior year quarter. However, non-GAAP diluted EPS rose 55.8% to $1.34. US spine sales grew 7%, whilst international spine sales increased 14% as-reported and 12% on a constant currency basis. Excluding Nevro, overall revenue growth was 9%. The musculoskeletal technology company reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion. It raised its non-GAAP fully diluted EPS guidance to $4.95 to $5.05 from the previous range of $4.70 to $4.80.

Yahoo Finance
Jul 21st, 2026
Globus Medical grows 27% as spine device maker raises guidance by 30 cents

Globus Medical reported strong first-quarter 2026 results, with revenue climbing 27% year-over-year to nearly $760 million and earnings per share rising to $1.12 from 68 cents, both exceeding analyst expectations. The $11 billion medical device company, which designs implantable devices and surgical instruments for spinal disorders, attributes growth to expanding market share, operational discipline, and dozens of new product launches. The company's US business has posted three consecutive quarters of at least 10% growth, whilst its international segment and enabling technologies division are also expanding. Following the strong performance, Globus raised its full-year EPS guidance by 30 cents to a range of $4.70-$4.80. The firm continues receiving FDA clearances to expand its product lineup.

Yahoo Finance
Jun 22nd, 2026
Globus Medical shares surge 5.1% after Q1 earnings beat estimates

Globus Medical shares rose 5.1% to $79.23 following strong first-quarter 2026 results. The medical device company posted adjusted earnings per share of $1.12 and revenues of $759.9 million, both exceeding Zacks Consensus Estimates. The company is expected to report quarterly earnings of $1.12 per share in its upcoming report, representing a 30.2% year-on-year increase. Revenues are forecast at $787.34 million, up 5.6% from the previous year. The consensus EPS estimate has been revised 2.5% higher over the past 30 days. Globus Medical currently carries a Zacks Rank #2 (Buy). The stock has declined 10.3% over the past four weeks despite the recent surge.

Yahoo Finance
Jun 12th, 2026
Madison Small Cap Fund exits Globus Medical as $12B valuation surpasses intrinsic value estimate

Madison Small Cap Fund has sold its entire position in Globus Medical, Inc. (NYSE:GMED) after several years, citing valuation concerns as the company's market capitalisation reached $12 billion, according to its Q1 2026 investor letter. The fund sold at approximately $90 per share, above its intrinsic value estimate of $85. Globus Medical has successfully integrated its Nuvasive acquisition and continues strong adoption of its robotics platform. Madison said it will redirect capital towards smaller alternatives. In Q1 2026, Globus Medical generated revenue of $759.9 million, up 27% year-over-year. The company's market capitalisation now stands at $10.93 billion, with shares gaining 36.71% over the past 52 weeks. Hedge fund ownership increased to 52 funds in Q1 from 42 in the previous quarter.